Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)
September 20 2022 - 7:33AM
Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that
non-clinical data from its oral orexin receptor 2 (OX2R) agonist
discovery pipeline have been accepted for poster presentation at
the 26th Conference of the European Sleep Research Society meeting
(Sleep Europe 2022) being held on September 27-30, 2022, in Athens,
Greece. Centessa’s OX2R agonists are designed to directly target
the underlying pathophysiology of orexin neuron loss in narcolepsy
type 1 (NT1), with potential expansion into narcolepsy type 2
(NT2), and other sleep disorders.
The poster presentation will feature the non-clinical activity
profiles of small-molecule OX2R agonists from multiple lead
chemical series developed using structure-based drug design with an
OX2R protein stabilized in the agonist conformation (Sosei
Heptares’ Stabilized Receptor Technology (StaR®)), together with
CryoEM (cryogenic electron microscopy) and high-resolution protein
crystallography. These novel OX2R agonist compounds showed high
potency in activating recombinant human and endogenous mouse OX2Rs,
with more than a thousand-fold selectivity for OX2R compared to
OX1R. The OX2R agonists also showed efficacy in promoting
wakefulness and in reducing cataplexy events in NT1 model mice, and
increased wakefulness in healthy mice.
“Over the past year, we have made significant advances building
a deep pipeline of novel, potent and selective OX2R agonists,” said
Saurabh Saha, MD, PhD, Chief Executive Officer of Centessa.
“Centessa’s orexin program is led by some of the most experienced
and insightful scientists in this field. Our innovative pipeline is
both a testament to their expertise and strong validation of our
approach to structure-based drug design. We are encouraged by the
non-clinical data and are rapidly progressing several potentially
best-in-class oral small-molecule OX2R agonists through our
discovery pipeline.”
“We are excited to showcase some of our small-molecule OX2R
agonist discovery pipeline and share these data at Sleep Europe
2022,” said Mario Alberto Accardi, PhD, Head, Centessa Orexin
Program. “Additionally, as part of our ongoing commitment to
patients, we look forward to joining the entire narcolepsy
community in recognizing World Narcolepsy Day on September 22nd to
reinforce the critical need for broader disease awareness and
additional treatment options for narcolepsy and other sleep
disorders.”
Details of the poster are as follows:Title:
Novel Orexin Receptor-2 Agonists Developed Using Structure-based
Drug Design: Prototype Compounds Promote Wakefulness and Reduce
Cataplexy in Orexin/Ataxin-3 and WT MiceAbstract
number: 401 Poster code:
P001Presenters: Sarah Wurts Black, Karl Gibson,
Deborah S. Hartman Session name: Late Breaking
Abstracts Session details: September 29, 2022, at
12:15 PM (local time)
The abstract and additional meeting information can be found on
the Sleep Europe 2022 website at https://esrs.eu/sleep-congress/.
The poster will also be available on the Centessa website at
https://investors.centessa.com/events-presentations after the
conference concludes.
About Centessa PharmaceuticalsCentessa
Pharmaceuticals plc is a clinical-stage pharmaceutical company with
a Research & Development (“R&D”) innovation engine that
aims to discover, develop and ultimately deliver impactful
medicines to patients. Our programs span discovery-stage to
late-stage development and cover a range of high-value indications
in rare diseases and immuno-oncology. We are led by a management
team with extensive R&D experience, providing direct guidance
to our program teams to rapidly advance our candidates from
research through all stages of development. For more information,
visit www.centessa.com, which does not form part
of this release.
Forward Looking StatementsThis press release
contains forward-looking statements. These statements may be
identified by words such as “may,” “might,” “will,” “could,”
“would,” “should,” “expect,” “intend,” “plan,” “objective,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,”
“continue,” “ongoing,” “aim,” “seek,” and variations of these words
or similar expressions that are intended to identify
forward-looking statements. Any such statements in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including statements related to the
Company’s ability to deliver impactful medicines to patients; the
ability of our management team and board to drive execution of the
Company’s portfolio of programs; our asset-centric business model
and the intended advantages and benefits thereof; research and
clinical development plans and the timing thereof; the scope,
progress, results and costs of developing our product candidates or
any other future product candidates; the development and
therapeutic potential of our product candidates, including OX2R
agonists; strategy; regulatory matters, including the timing and
likelihood of initiating clinical trials, reporting clinical trial
results, submitting an IND and the success of obtaining
authorizations to initiate or continue clinical trials or market
any products; and the market size and opportunity for our product
candidates. Any forward-looking statements in this press release
are based on our current expectations, estimates and projections
only as of the date of this release and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks related to the safety and
tolerability profile of our product candidates; our ability to
protect and maintain our intellectual property position; business
(including commercial viability), regulatory, economic and
competitive risks, uncertainties, contingencies and assumptions
about the Company; risks inherent in developing product candidates
and technologies; future results from our ongoing and planned
clinical trials; our ability to obtain adequate financing,
including through our financing facility with Oberland, to fund our
planned clinical trials and other expenses; trends in the industry;
the legal and regulatory framework for the industry, including the
receipt and maintenance of clearances to conduct or continue
clinical testing; future expenditures risks related to our
asset-centric corporate model; the risk that any one or more of our
product candidates will not be successfully developed and/or
commercialized; the risk that the results of non-clinical studies
or clinical studies will not be predictive of future results in
connection with future studies; geo-political risks such as the
Russia-Ukraine war and risks related to the ongoing COVID-19
pandemic including the effects of the Delta, Omicron and any other
variants. These and other risks concerning our programs and
operations are described in additional detail in our Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q, and our other
reports, which are on file with the U.S. Securities and Exchange
Commission (SEC). We explicitly disclaim any obligation to update
any forward-looking statements except to the extent required by
law.
Contact:
Kristen K. Sheppard, Esq.SVP of Investor Relations
investors@centessa.com
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Sep 2023 to Sep 2024